Opiate Analgesic Use in Pediatric Patients Bob Rappaport, M.D. Deputy Division Director Division of Anesthetic, Critical Care and Addiction Drug Products,

Slides:



Advertisements
Similar presentations
Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.
Advertisements

Development of Evaluation and Consultation on Bridging Studies: Thailand Experiences Suchart Chongprasert, Ph.D. Investigational New Drug Subdivision Food.
Susan Boynton, VP, Global Regulatory Affairs, Shire
Artesunate Rectal Capsules For the initial management of acute malaria in patients who cannot take medication by mouth and for whom parenteral treatment.
Great Ormond Street Hospital for Children NHS Trust The School of Pharmacy UCL INSTITUTE OF CHILD HEALTH Centre for Paediatric Pharmacy Research Drug Development.
Daniel J. Isaacman, m.D., FAAP
RISK EVALUATION AND MITIGATION STRATEGIES FOR LONG-ACTING OPIOID ANALGESICS REMS Katherine E. Galluzzi, D.O., CMD, FACOFP dist. Chair – AOA Council on.
Mosby items and derived items © 2005, 2002 by Mosby, Inc. CHAPTER 9 Drug Administration.
Overview of the Clinical Development EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use. ASENT 12 th Annual.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Methylphenidate Transdermal Patch Paul J. Andreason, MD Acting Deputy Director Division of Psychiatry Products Center for Drug Evaluation and Research,
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health 1 Regulatory Requirements.
Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.
The Impact of IMMPACT Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia and Rheumatology Products Center for Drug Evaluation and Research.
Joint NDAC/PAC meeting October 18, 2007 OTC Cold and Cough Products: Use in Children Advisory Committee Meeting October 18, 2007 Joel Schiffenbauer, MD.
1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.
Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 13 & 14, 2008 History of OxyContin: Labeling and Risk.
Chapter 4 Medication Preparations and Supplies. Copyright © 2007 by Thomson Delmar Learning. ALL RIGHTS RESERVED.2 Medication Terms Drug form –Type of.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.
Michael V. Novinski President and Chief Executive Officer July 29, 2008 Eligen ® B12 – Human Clinical Results.
Basis for Neulasta® (Pegfilgrastim) Approval
1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.
Practice Guidelines for the Prevention, Detection, and Management of Respiratory Depression Associated with Neuraxial Opioid Administration Troy Tada,
Slide 1 Overview of the Drug Formulary Commission and Statutory Objectives Bureau of Health Care Safety and Quality Department of Public Health August.
1 The ACTION Public-Private Partnership: Background, Rationale, and Objectives Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia, and Addiction.
REGULATION OF CLINICAL TRIALS IN PAEDIATRIC POPULATION DIFFERENCES BETWEEN TRIALS IN ADULTS AND CHILDREN presented by GYURASICS, ÁGNES MD PhD National.
Section 1 Introduction to Pharmacology Humans have been treating diseases with substances around them for over 4000 yrs. These “drugs’ were chosen.
1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.
Methods of Drug Delivery
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Week 6- Bioavailability and Bioequivalence
1 Ethical issues in clinical trials Bernard Lo, M.D. February 10, 2010.
Drug - Device Combination Issues : Oncology Perspective Ramzi Dagher, M.D. DODP/CDER/FDA.
Bioavailability Dr Mohammad Issa.
History of Pediatric Labeling
Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Question 1 Pozen estimated an annual incidence of tardive dyskinesia (TD) of up to 0.038% for metoclopramide at a daily dose of mg/day for 72 days/year.
Long-Term Efficacy Data for Psychiatric Drugs Thomas Laughren, M.D. Director, Division of Psychiatry Products (HFD-130) PDAC Meeting (Oct 25, 2005)
“Breakthrough” in Chronic Non-Cancer Pain: A Proposed Indication in Need of Further Study Prepared for: Joint Meeting of the Anesthetic and Life Support.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 9 Photo Atlas of Drug Administration.
Mosby items and derived items © 2005, 2002 by Mosby, Inc. CHAPTER 9 Drug Administration NDEG 26 A - Pharmacology 1 Eliza Rivera-Mitu, RN, MSN.
Initiatives Drive Pediatric Drug Development January 30, 2002.
Risk Management of Modified- Release Opiate Analgesics: Palladone Sharon Hertz, M.D. Medical Team Leader, Analgesics Division of Anesthetic, Critical Care,
Ethical issues with the regulatory use of gene expression data Benjamin S Wilfond MD Medical Genetics Branch National Human Genome Research Institute Department.
1/11/01 Pediatric trials for ARV experienced children Coleen K. Cunningham Epidemiology of treatment experience in pediatrics How does the smaller number.
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.
Application of the 1998 Pediatric Rule to Oncology Steven Hirschfeld, MD PhD CDR U.S. Public Health Service Medical Officer Division of Oncology Drug Products.
ASENT/ISCTM, Feb 23 rd, 2012, Washington DC, USA Pharmaceuticals & Medical Devices Agency Pediatric Drug Development for Neuro-Psychiatric Diseases Yoshiaki.
Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.
Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.
Recent FDA Activities in Safe Use of Opioids Bob Rappaport, M.D. Director, Division of Anesthesia, Analgesia, and Addiction Products Center for Drug Evaluation.
Chapter 13 Pain Management.
Regulatory Considerations for Approval: FDA perspective
ANALGESIC, ANESTHETIC, AND ADDICTION CLINICAL TRIAL TRANSLATIONS, INNOVATIONS, OPPORTUNITIES, AND NETWORKS (ACTTION) Public-Private Partnership WITH.
Division of Cardiovascular Devices
*Risk Evaluation and Mitigation Strategy
FDA’s IDE Decisions and Communications
Clinical Trials — A Closer Look
Concepts of Paediatric Investigation Plans (PIP)
MEDICATION ADMINISTRATION
An Intro into Pharmacology
Suzanne M. Sensabaugh, MS, MBA
Pediatric Clinical investigator training workshop
Senior Medical Officer Division of Antiviral Products OAP/OND/CDER/FDA
Pediatric Therapeutics Still working to get it right for kids
Pediatric Drug Development A Regulatory Perspective
Presentation transcript:

Opiate Analgesic Use in Pediatric Patients Bob Rappaport, M.D. Deputy Division Director Division of Anesthetic, Critical Care and Addiction Drug Products, FDA

Hypothetical Vignettes in Pediatric Drug Development

DRUG 1 Novel long-acting sustained release opiate Multiple-dose PK study in children > 7 years Efficacy not a primary endpoint -can we extrapolate from adults? -reliability of endpoints in children Pediatric waiver requested for  7 years -“substantial use” -recruitment -lowest dose dangerously high

Discussion points: Efficacy endpoints in pediatric age groups Pediatric recruitment for long term analgesic trials Appropriateness of formulations -tablets/capsules, etc -age groups Use of long-acting opiates in children

Discussion points: Pediatric Rule: study pediatric-appropriate formulations Sponsor arguments: New formulation would not retain sustained-release features No meaningful therapeutic benefit over existing No plans to market Value of requiring new formulation studies?

DRUG 2 New delivery system for chronic malignant pain >24 hrs: reservoir adherent to skin continuous SQ (25G needle) previously approved intermediate-duration opioid (adult only) PCA boluses Pediatric waiver requested for  12 years Unsafe (dislodgment of needle) PCA inappropriate PCA boluses too large

Discussion Points: Appropriate age groups for: Continuous infusion devices Patient-controlled dosing Needle delivery devices Devices applied externally over a period of time Value of mandating studies of a pediatric- appropriate formulation (e.g. oral, IV) without the subcutaneous injection device

DRUG 3 New fixed-dose opioid-acetaminophen combination Pediatric waiver requested Are fixed dose combinations inappropriate in this setting? IRB: Analgesic trials unethical in children (especially placebo-controlled)

Discussion Points: Fixed-dose opioid combination drugs: appropriateness, dosing considerations Ethical concerns in pediatric analgesic trials Types of trials (e.g. placebo-controlled) Age groups

Currently Available Formulations (Majority without pediatric indications) Powder Injectable Oral –concentrate, solution, suspension, suspension XR, syrup, elixir, tablet, tablet XR, capsule, capsule XR, lozenge Transdermal Film Nasal Rectal Suppository Intrathecal Epidural

The FDA is aware that there are still significant unmet needs in pediatric pain management. In the context of the Agency's new mandate to require studies of drugs in children, discuss these unmet pharmacotherapeutic needs in current pediatric pain management and how they might be met with regard to opioid drug products. Include discussion of the significance of barriers to opioid analgesic trials in children (ethical, safety, scientific, practical, etc), and what strategies might be used to overcome those barriers?

Many different opioid formulations, delivery methods, and drug ‑ device combinations are currently on the market or may be available in the future. Discuss the age appropriateness and limitations of these various methods of administration, as well as any others that may be particularly useful or particularly hazardous in the treatment of pediatric pain patients.

It has been historically accepted that the mechanisms of action of opioid analgesics are sufficiently similar between adults and children that large controlled studies to demonstrate efficacy have not been required for a pediatric indication. Instead, pediatric trials have been largely focused on investigating safety, pharmacokinetics and appropriate dosing regimens. Discuss the shortfalls, if any, to this approach. Include discussion of approaches to dose finding and the evaluation of pain in the very young.

As new opiate analgesic products become available for home use in younger patients, there may be a risk of accidental ingestion by family members, or deliberate abuse and diversion of these medications. Discuss the strategies for risk communication and risk management that should be considered at the time of pediatric opioid drug approval.